Wednesday, February 21, 2024

Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed

Cabotegravir and rilpivirine were superior in suppressing HIV replication compared to daily oral ART.
NIH/NIAID Template Banner

Wednesday, February 21, 2024

Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed

Three light orange ovals with blue and purple speckled matter across half of the image surface.

Colorized transmission electron micrograph of HIV-1 virus particles (light orange) budding and replicating from an H9 T cell (blue/purple). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland.

Credit: NIAID

Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a NIAID-sponsored randomized trial. Upon review of these findings, an independent Data and Safety Monitoring Board (DSMB) recommended halting randomization and inviting all eligible study participants to take long-acting ART. NIAID accepted the DSMB's recommendation.

Read More


This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

No comments:

Post a Comment